evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,970 questions · 2,433 findings · 231 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 303 · 12.5%GRADE not reported 759 · 31.2%Very low 357 · 14.7%Low 476 · 19.6%Moderate 418 · 17.2%High 120 · 4.9%

38% silver diamine fluoride vs Glass ionomer cement (GIC) plus fluoride varnish

Caries prevention (preventive fraction, SDF vs GIC+5% fluoride varnish) · intellectually disabled individuals with caries in permanent posterior teeth

SDF had a 45% preventative fraction versus glass ionomer cement plus fluoride varnish; no pooled estimate or GRADE rating was reported.

1 finding from 1 review

Prosthetic need vs Individuals without prosthetic need

Oral health-related quality of life · Indian elderly and general-population adults

Prosthetic need was significantly associated with poorer OHRQoL in both included studies (moderate certainty).

3 findings from 1 review

Dental caries assessment (WHO/clinical diagnostic criteria; caries = DMFT>0) vs Caries-free status

CA VI activity · Children (age about 2-9 years) across the 7 meta-analyzed activity samples; excludes Kivela 1999 adults (18-24 years), qualitative only…

Salivary/biofilm CA VI activity is significantly higher in individuals with dental caries than in caries-free individuals (SMD 0.894, 95% CI 0.386 to 1.392; not GRADE-rated).

1 finding from 1 review

Dental fluorosis (assessed by TFI or WHO criteria) vs Individuals without dental fluorosis

Oral health-related quality of life · Indian children and young adults

Two studies found dental fluorosis significantly associated with poorer OHRQoL; narrative, ungraded.

1 finding from 1 review

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

Survival · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype
1 finding from 1 review

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

Quality of life: total score · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

FEV1 % predicted: relative change from baseline · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

FEV1 % predicted: absolute change from baseline · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype
1 finding from 1 review

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

Adverse events ‐ treatment emergent · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor showed no clear difference in adverse events: number of participants with treatment‐emergent… compared with control (ivacaftor alone or tezacaftor plus ivacaftor) (moderate certainty).

1 finding from 1 review

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

Time to first pulmonary exacerbation · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype

The review found no eligible studies for this question.

1 finding from 1 review

Brief intervention vs brief advice, information, or assessment only

Harmful alcohol use · people with hazardous or harmful alcohol consumption
2 findings from 1 review

Any Psychosocial intervention plus pharm vs psychosocial interventions

Harmful alcohol use · alcohol use disorder
2 findings from 1 review

Any Psychosocial intervention plus pharm vs psychosocial interventions

Retention [ · alcohol use disorder

Pharmacologic intervention along with psychosocial intervention showed no clear difference in retention compared with psychosocial intervention alone (moderate certainty).

1 finding from 1 review